Chemomab Therapeutics Ltd expected to post a loss of 4 cents a share - Earnings Preview

Chemomab Therapeutics

09/05/2023 13:01

* Chemomab Therapeutics Ltd  CMMB.OQ   CMMB.O  is expected
to show
no change in quarterly revenue when it reports  results on May
11. 
    * 
    * ​Refinitiv's mean analyst estimate for Chemomab
Therapeutics Ltd
is for a loss of 4 cents per share. 
    * The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 2 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts had risen by
about 94.1%
in the last three months. ​
    * Wall Street's median 12-month price target for Chemomab
Therapeutics Ltd is $12​, above​ its last closing price
of $1.54. ​​​

This summary was machine generated May 9 at 12:00 GMT.  All
figures in US dollars  unless otherwise stated